Cleantech Solutions International (CLNT) Reaches $4.48 After 7.00% Up Move, Durect (DRRX) Sellers Increased By 30.98% Their Shorts

May 29, 2017 - By Maria Brooks

The stock of Cleantech Solutions International Inc (NASDAQ:CLNT) is a huge mover today! The stock increased 12.00% or $0.48 on May 26, reaching $4.48. About 1.45M shares traded or 50.81% up from the average. Cleantech Solutions International Inc (NASDAQ:CLNT) has declined 3.23% since May 29, 2016 and is downtrending. It has underperformed by 19.93% the S&P500.The move comes after 6 months positive chart setup for the $7.18M company. It was reported on May, 29 by Barchart.com. We have $4.79 PT which if reached, will make NASDAQ:CLNT worth $502,600 more.

Durect Corporation (NASDAQ:DRRX) had an increase of 30.98% in short interest. DRRX’s SI was 2.88 million shares in May as released by FINRA. Its up 30.98% from 2.20M shares previously. With 402,800 avg volume, 7 days are for Durect Corporation (NASDAQ:DRRX)’s short sellers to cover DRRX’s short positions. The SI to Durect Corporation’s float is 2.4%. The stock increased 1.59% or $0.02 on May 26, reaching $1.28. About 1.16M shares traded. DURECT Corporation (NASDAQ:DRRX) has risen 7.89% since May 29, 2016 and is uptrending. It has underperformed by 8.81% the S&P500.

Cleantech Solutions International, Inc., through its subsidiaries, makes and sells textile dyeing and finishing machines and sells forged products and fabricated products to a range of clean technology customers, including high precision forged rolled rings and related components for the wind power industry and other industries. The company has market cap of $7.18 million. The Firm operates through three divisions: dyeing and finishing equipment segment, forged rolled rings and related components segment, and petroleum and chemical equipment segment. It currently has negative earnings. Through its dyeing and finishing equipment segment, the Company designs, makes and distributes a line of high and low temperature dyeing and finishing machinery to the textile industry.

Investors sentiment increased to 1.24 in Q4 2016. Its up 0.04, from 1.2 in 2016Q3. It improved, as 14 investors sold DURECT Corporation shares while 19 reduced holdings. 14 funds opened positions while 27 raised stakes. 68.34 million shares or 4.24% more from 65.56 million shares in 2016Q3 were reported. National Bank & Trust Of America De has invested 0% of its portfolio in DURECT Corporation (NASDAQ:DRRX). 136,520 are held by Rhumbline Advisers. Price T Rowe Assoc Inc Md accumulated 90,530 shares. The New York-based Art Advisors Ltd Company has invested 0% in DURECT Corporation (NASDAQ:DRRX). Tocqueville Asset Management Limited Partnership stated it has 506,000 shares. Bridgeway Mngmt Inc holds 0.01% of its portfolio in DURECT Corporation (NASDAQ:DRRX) for 624,000 shares. Hsbc Public Ltd Liability Corp stated it has 21,741 shares. Sabby Management Limited Liability has 0.12% invested in DURECT Corporation (NASDAQ:DRRX) for 1.53 million shares. Connecticut-based Paloma Prns Management Co has invested 0% in DURECT Corporation (NASDAQ:DRRX). Kings Point Capital Mgmt stated it has 655,000 shares or 0.22% of all its holdings. Nationwide Fund Advisors holds 0% or 79,147 shares in its portfolio. First Eagle Investment Limited Company has invested 0.08% in DURECT Corporation (NASDAQ:DRRX). 54,163 are owned by Credit Suisse Ag. Regis Co Ltd Liability stated it has 0.03% in DURECT Corporation (NASDAQ:DRRX). Moreover, Raymond James And has 0% invested in DURECT Corporation (NASDAQ:DRRX).

Durect Corporation is a biopharmaceutical firm with research and development programs. The company has market cap of $184.60 million. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. It currently has negative earnings. The Company’s other product candidates include POSIMIR , REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR opioid (hydromorphone) and SABER ophthalmic.